Unknown

Dataset Information

0

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.

ABSTRACT: Poly(ADP-ribose) polymerase (PARP) inhibitors have proven to be successful agents in inducing synthetic lethality in several malignancies. Several PARP inhibitors have reached clinical trial testing for treatment in different cancers, and, recently, Olaparib (AZD2281) has gained both United States Food and Drug Administration (USFDA) and the European Commission (EC) approval for use in BRCA-mutated advanced ovarian cancer treatment. The need to identify biomarkers, their interactions in DNA damage repair pathways, and their potential utility in identifying patients who are candidates for PARP inhibitor treatment is well recognized. In this review, we detail many of the biomarkers that have been investigated for their ability to predict both PARP inhibitor sensitivity and resistance in preclinical studies as well as the results of several clinical trials that have tested the safety and efficacy of different PARP inhibitor agents in BRCA and non-BRCA-mutated cancers.

SUBMITTER: Murata S 

PROVIDER: S-EPMC5013223 | biostudies-other | 2016

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.

Murata Stephen S   Zhang Catherine C   Finch Nathan N   Zhang Kevin K   Campo Loredana L   Breuer Eun-Kyoung EK  

BioMed research international 20160824

Poly(ADP-ribose) polymerase (PARP) inhibitors have proven to be successful agents in inducing synthetic lethality in several malignancies. Several PARP inhibitors have reached clinical trial testing for treatment in different cancers, and, recently, Olaparib (AZD2281) has gained both United States Food and Drug Administration (USFDA) and the European Commission (EC) approval for use in BRCA-mutated advanced ovarian cancer treatment. The need to identify biomarkers, their interactions in DNA dama  ...[more]

Similar Datasets

Unknown PARP inhibitors: Synthetic lethality in the clinic.
| S-EPMC6175050 | biostudies-literature
Unknown Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
| S-EPMC8211653 | biostudies-literature
Unknown New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
| S-EPMC5927601 | biostudies-literature
Unknown ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
| S-EPMC11369084 | biostudies-literature
Other Transcription-Replication Conflicts drive the Synthetic Lethality of PARP Inhibitors with BRCA2-Deficiency
2024-04-12 | GSE220223 | GEO
Unknown Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
| S-EPMC5576028 | biostudies-literature
Unknown Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors.
| S-EPMC6082654 | biostudies-literature
Unknown The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
| S-EPMC8238121 | biostudies-literature
Unknown LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
| S-EPMC6752209 | biostudies-literature
Unknown Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
| S-EPMC5315641 | biostudies-literature